These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Mutational and structural analysis of KIR3DL1 reveals a lineage-defining allotypic dimorphism that impacts both HLA and peptide sensitivity. O'Connor GM; Vivian JP; Widjaja JM; Bridgeman JS; Gostick E; Lafont BA; Anderson SK; Price DA; Brooks AG; Rossjohn J; McVicar DW J Immunol; 2014 Mar; 192(6):2875-84. PubMed ID: 24563253 [TBL] [Abstract][Full Text] [Related]
10. The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity. Salih J; Hilpert J; Placke T; Grünebach F; Steinle A; Salih HR; Krusch M Int J Cancer; 2010 Nov; 127(9):2119-28. PubMed ID: 20143399 [TBL] [Abstract][Full Text] [Related]
11. HIV protective KIR3DL1 and HLA-B genotypes influence NK cell function following stimulation with HLA-devoid cells. Boulet S; Song R; Kamya P; Bruneau J; Shoukry NH; Tsoukas CM; Bernard NF J Immunol; 2010 Feb; 184(4):2057-64. PubMed ID: 20061407 [TBL] [Abstract][Full Text] [Related]
12. KIR3DL1 and HLA-B Density and Binding Calibrate NK Education and Response to HIV. Boudreau JE; Mulrooney TJ; Le Luduec JB; Barker E; Hsu KC J Immunol; 2016 Apr; 196(8):3398-410. PubMed ID: 26962229 [TBL] [Abstract][Full Text] [Related]
13. HLA-Bw4 80(T) and multiple HLA-Bw4 copies combined with KIR3DL1 associate with spontaneous clearance of HCV infection in people who inject drugs. Thöns C; Senff T; Hydes TJ; Manser AR; Heinemann FM; Heinold A; Heilmann M; Kim AY; Uhrberg M; Scherbaum N; Lauer GM; Khakoo SI; Timm J J Hepatol; 2017 Sep; 67(3):462-470. PubMed ID: 28412292 [TBL] [Abstract][Full Text] [Related]
14. NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice. Chen CI; Koschmieder S; Kerstiens L; Schemionek M; Altvater B; Pscherer S; Gerss J; Maecker HT; Berdel WE; Juergens H; Lee PP; Rossig C Leukemia; 2012 Mar; 26(3):465-74. PubMed ID: 21904381 [TBL] [Abstract][Full Text] [Related]
15. A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1 Gleixner KV; Sadovnik I; Schneeweiss M; Eisenwort G; Byrgazov K; Stefanzl G; Berger D; Herrmann H; Hadzijusufovic E; Lion T; Valent P Leuk Res; 2019 Mar; 78():36-44. PubMed ID: 30711891 [TBL] [Abstract][Full Text] [Related]
16. Phenotypical and functional profiles of natural killer cells exhibiting matrix metalloproteinase-mediated CD16 cleavage after anti-HIV antibody-dependent activation. Tang CC; Isitman G; Bruneau J; Tremblay C; Bernard NF; Kent SJ; Parsons MS Clin Exp Immunol; 2015 Aug; 181(2):275-85. PubMed ID: 25644502 [TBL] [Abstract][Full Text] [Related]
17. Interactions of NK cell receptor KIR3DL1*004 with chaperones and conformation-specific antibody reveal a functional folded state as well as predominant intracellular retention. Taner SB; Pando MJ; Roberts A; Schellekens J; Marsh SG; Malmberg KJ; Parham P; Brodsky FM J Immunol; 2011 Jan; 186(1):62-72. PubMed ID: 21115737 [TBL] [Abstract][Full Text] [Related]
18. The interaction of KIR3DL1*001 with HLA class I molecules is dependent upon molecular microarchitecture within the Bw4 epitope. Saunders PM; Vivian JP; Baschuk N; Beddoe T; Widjaja J; O'Connor GM; Hitchen C; Pymm P; Andrews DM; Gras S; McVicar DW; Rossjohn J; Brooks AG J Immunol; 2015 Jan; 194(2):781-789. PubMed ID: 25480565 [TBL] [Abstract][Full Text] [Related]